Health technology company CytoSorbents Corp. has moved its global headquarters from Monmouth Junction down the road to Princeton.
CytoSorbents specializes in blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients.
The mixed-use facility will accommodate all U.S. administrative, clinical, commercialization, manufacturing, and research and development activities.
The lease will begin on June 1.
The new building will not only meet the company’s needs, but with other modifications, allow the launch of new product lines.
“The changes we are planning will also allow us to increase our CytoSorb production from our current $80 million annual capacity to approximately $300 to $400 million annually to support our future growth while allowing us to achieve further economies of scale,” said President and COO Vincent Capponi in a prepared statement.
Capponi said they plan to use the Deer Park manufacturing facility in Monmouth Junction through Dec. 31, 2022.